COMMUNIQUÉS West-GlobeNewswire

Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, at 2025 World Congress on Osteoarthritis

26/04/2025 - 10:00

Plenary presentation of data showing primary efficacy endpoint met – significant analgesia across all doses Significant improvement in all signs and symptoms of osteoarthritis for all doses Poster presentation of [...]

VitaSeal Reviews (EXPERT OPINION) Does VitaSeal Really Work For Diabetes or Is It Just Hype? (Pros & Cons)

26/04/2025 - 06:57

MINNEAPOLIS, April 26, 2025 (GLOBE NEWSWIRE) -- VitaSeal is a natural blood sugar control formula that has been receiving much hype lately. The manufacturer claims this supplement is a combination of natural ingredients [...]

Gluco6 Reviews (SHOCKING RESULTS) Is This Herbal Formula Control Blood Sugar Effectively or Over Hype?

26/04/2025 - 06:57

LOS ANGELES, April 26, 2025 (GLOBE NEWSWIRE) -- Gluco6 is a natural blood sugar support supplement emerging as a popular choice in the ever-growing market of anti-diabetic supplements. The formula targets some key [...]

Mitolyn Reviews 2025 (WARNING) Purple Peel Exploit Scientific Evidence, Complaints & What the Users Says About Mitochondrial Support!

26/04/2025 - 07:03

New York City, April 26, 2025 (GLOBE NEWSWIRE) -- More individuals wish to lose weight, feel more energetic, and become healthier. While most weight loss supplements offer immediate results, they can damage your long- [...]

Hgh X2 Reviews 2025: Dosage ,Side Effects, Cycle (Human Growth Hormone For Muscle Growth) - HGH for Bodybuilding By Crazy Bulk

26/04/2025 - 07:42

New York City, April 26, 2025 (GLOBE NEWSWIRE) -- In bodybuilding, optimal muscle gain, strength, and bodybuilding are surpassed with intense training and strict dieting. For such a bodybuilder looking for a legal, [...]

Financière de Tubize - Approbation du dividende

26/04/2025 - 08:00

Approbation du dividende Information réglementée - 25 avril 2025 L’assemblée générale des actionnaires du 25 avril 2025 a approuvé les comptes annuels relatifs à l’exercice social clôturé le 31 décembre 2024, en ce [...]

Financière de Tubize - Dividend approval

26/04/2025 - 08:00

Dividend confirmation Regulated information - 25 april 2025 The general shareholders meeting of 25 April 2025 has approved the annual accounts as at 31 December 2024, including the distribution of a gross dividend of € [...]

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

26/04/2025 - 02:06

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced [...]

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

25/04/2025 - 22:05

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating [...]

SRx Health Solutions, Inc. (formerly known as Better Choice Company Inc.) Announces Halo Spin-Out Distribution for Stockholders of Record as of April 23, 2025

25/04/2025 - 22:05

TAMPA, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (formerly known as Better Choice Company Inc.) (NYSE American: BTTR) (the “Company”), a leading global health and wellness company, today [...]

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

25/04/2025 - 22:05

IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the [...]

Prelude Announces Presentations at 2025 AACR Annual Meeting

25/04/2025 - 22:05

Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and [...]

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

25/04/2025 - 22:05

Podium presentation showcases the clinical application of Precise™ MRD SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision [...]

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

25/04/2025 - 22:15

FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve [...]

Rezolute, Inc. Announces Closing of Underwritten Offering

25/04/2025 - 22:30

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare [...]

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

25/04/2025 - 23:30

FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company [...]

Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025

25/04/2025 - 19:10

PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced [...]

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

25/04/2025 - 19:10

- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2 ) was well-tolerated and demonstrated promising [...]

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

25/04/2025 - 19:17

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse [...]